The daily dosage of orelabrutinib shall be determined based on the patient’s disease condition, physical status, and the physician’s instructions. Under normal circumstances, the recommended dosage for adults is 150 mg administered orally once daily (equivalent to one tablet of 150 mg strength). The specific dosage must strictly follow the physician’s advice, and shall not be adjusted without authorization.
I. Dosage Rationale and Individualized Adjustment
1. Type and Stage of Disease
Orelabrutinib is primarily indicated for the treatment of certain B-cell malignancies (e.g., mantle cell lymphoma, chronic lymphocytic leukemia, etc.). The specific dosage may vary depending on the tumor type, stage, and the patient’s response to the drug. For instance, a fixed daily dosage of 150 mg has been adopted in some clinical trials, but adjustments should be made based on the patient’s actual condition.
2. Patient’s Physical Status
In cases of abnormal liver or kidney function, comorbidities, or concurrent use of other medications, the physician may adjust the dosage. For example, patients with moderate to severe hepatic impairment may require dosage reduction.
3. Treatment Phase and Efficacy Evaluation
The standard dosage is generally administered during the initial treatment phase, followed by dynamic adjustments based on efficacy (e.g., hematological parameters, imaging examinations) and adverse reaction profiles. If severe adverse reactions occur (e.g., infection, hemorrhage, etc.), temporary treatment suspension or dosage reduction may be necessary.
II. Precautions for Administration
Timing and Method of Administration
It is recommended to take the medication at a fixed time every day (e.g., morning or evening). Swallow the tablet whole; do not chew or crush it. Whether to take it on an empty stomach or with meals shall be in accordance with the product label or the physician’s instructions.
Management of Missed Dose
If a dose is missed, take the missed dose as soon as possible on the same day. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule; do not take a double dose.
Drug Interactions
Orelabrutinib may interact with anticoagulants, immunosuppressants, and other medications. Patients should inform their physicians of all other medications they are taking (including over-the-counter drugs and health supplements).
III. Administration in Special Populations
1. Elderly Patients
Elderly patients may require dosage adjustment due to age-related decline in metabolic function, but dosage reduction based solely on age is generally not necessary. The decision should be made based on the evaluation of liver and kidney function.
2. Patients with Abnormal Liver or Kidney Function
Patients with moderate to severe hepatic impairment (Child-Pugh Class B/C) or severe renal impairment may require dosage reduction to 100 mg daily or lower, which must be strictly in accordance with the physician’s instructions.
3. Pregnancy and Lactation
Orelabrutinib may cause harm to the fetus and is contraindicated during pregnancy. Breastfeeding should be discontinued during treatment with this medication.
IV. Long-term Medication and Follow-up
Regular Monitoring
During treatment, regular monitoring including complete blood count, liver and kidney function tests, and electrocardiogram is required to assess treatment efficacy and drug safety.
Adverse Reaction Management
Common adverse reactions include thrombocytopenia, neutropenia, and diarrhea. If symptoms such as fever, persistent headache, or abnormal bleeding occur, medical attention should be sought immediately.
Storage Conditions
Store the medication below 30℃ away from light and moisture, and keep it out of the reach of children.
V. Important Reminders
1. Do Not Adjust Dosage Without Authorization
Patients must take the medication strictly as prescribed. Even if symptoms improve, treatment shall not be discontinued or the dosage altered arbitrarily.
2. Individualized Treatment Regimen
There are significant variations in drug metabolism rate and tolerance among different patients. An individualized treatment plan should be formulated based on the physician’s comprehensive assessment.
3. Reference to Clinical Trial Data
The current recommended dosage is primarily based on clinical trial results. Dynamic adjustments should still be made according to the patient’s specific condition in clinical practice.
In case of any questions or discomfort, patients should promptly consult their attending physician to ensure the safety and efficacy of treatment.
